Article
Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report.
Oncology reports - 1 Sept 2022
Unk Mojca, Bombač Alenka, Jezeršek Novaković Barbara, Stegel Vida, Šetrajčič Dragoš Vita, Blatnik Olga, Klančar Gašper, Novaković Srdjan
Abstract excerpt
In patients with gastrointestinal stromal tumors (GIST), it has become mandatory to determine the driver mutation in order to predict the response to standard treatment with tyrosine kinase inhibitors (TKI). A total of 10‑15% of all GIST lack activating mutations in KIT proto‑oncogene, receptor tyrosine kinase (KIT)/platelet‑derived growth factor receptor alpha (PDGFRA) and have been classified as KIT/PDGFRA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.